Hemofarm a.d.
 | |
Native name | Хемофарм а.д. |
|---|---|
| Public limited company | |
| Industry | Pharmaceuticals |
| Founded |
Vršac, Serbia (August 28, 1998) First founded 1960 |
| Headquarters | Vršac, Serbia |
Key people | Ronald Seeliger (CEO) |
| Products | Pharmaceuticals, Prescription drugs |
| Revenue |
 €258.54 million (2013)[1] |
|
€26.22 million (2013)[1] | |
| Total assets |
€312.20 million (2013)[1] |
| Total equity |
€193.80 million (2013)[1] |
| Owner | STADA (100%) |
Number of employees | 2,484[1] |
| Website |
www |
Hemofarm a.d. (full legal name: Hemofarm a.d. Farmaceutsko-hemijska industrija Vršac), a member of STADA Group, is a Serbian pharmaceutical company based in Vršac, Serbia. Founded in 1960, it is one of the largest domestic producer and exporter of medicines in Serbia. Hemofarm currently operates in more than 30 countries on 3 continents and has approximately 2,500 employees.
The core activity represents the manufacture of high-quality, effective, safe and affordable Rx and OTC medicines and products of the latest generation, in all known forms and groups through implementation of the cutting-edge technologies. Portfolio includes over 140 INNs, with about 280 forms and dosage forms. Over the counter (OTC) medicines of Hemofarm keep the leading position in the Serbian market.
History
Hemofarm was founded on June 1, 1960 in Vršac. In 2003 it opened the first factory for the production of medicine in the Republika Srpska. As of 2003 Hemofarm consisted of 21 subsidiaries, 12 of which were located in Serbia and Montenegro.[2]
In 2004, the company acquired four other Serbian concerns, increasing its market share from 15% to 45% in the process.[3] As of 2011, the company has a market share in terms of production and import of 30.7%.[4]
Hemofarm was bought by the German STADA Arzneimittel pharmaceutical group for 480 million euros in 2006.[5] Since August 9, 2009 Hemofarm has been a member of the German STADA Group.
Research and development
Hemofarm’s R&D division was established in 1990, and it has been recognized by STADA as a competence center for development of new generic products not only for local and regional markets, but also for the whole STADA Group. An intensive development of products intended for registration and sale in the demanding European Union market started in 2007.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Основни подаци из консолидованог финансијског извештаја за 2013. годину. Agencija za privredne registre Srbije (in Serbian). Retrieved 17 June 2014.
- ↑ "Bosnian Serb, Serbian premiers inaugurate pharmaceutical plant". Asia Africa Intelligence Wire. February 21, 2003. Retrieved 2008-10-02.
- ↑ Doing Business with Serbia By Marat Terterov, Consultant Editor, Marat Terterov, Inc NetLibrary; Published by GMB Publishing Ltd, 2006; ISBN 1-905050-68-2, ISBN 978-1-905050-68-0.
- ↑ Lazarević, Igor. "Konsolidacija farmaceutskog tržišta Srbije". scribd.com (in Serbian). Retrieved 28 July 2014.
- ↑ "Stada Says Strength of Russian Unit May Attract Bids". Blommberg. 11 January 2013. Retrieved 9 April 2013.